Clinical Trials Browser

Phase 2 × Carcinoma, Transitional Cell × tipifarnib × Clear all

NCT02535650 2022-03-08

Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma

Phase 2 Unknown

Carcinoma, Transitional Cell